Liver Illness and Psychiatric Patients

Carrier, Paul; Debette-Gratien, Marilyne; Girard, M.; Jacques, J.; Nubukpo, Philippe; Loustaud‐Ratti, Véronique

doi:10.5812/hepatmon.41564

Cited by 20 publications

(21 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Liver dysfunctions may be due to the repeated and long-term exposure to toxic substances (alcohol, tobacco, etc,) in manic patients. 43 Moreover, our results showed that the prevalence of hypothyroidism is 5.1% similar to what is found in the literature, 6,17 while the prevalence of hyperthyroidism was similar to that reported worldwide. 17,44 In fact, the prevalence of hyperthyroidism is not common in BD-I and does not exceed 2%.…”

Section: Discussionsupporting

confidence: 89%

Prevalence of comorbidities and correlates of hospital readmission rate in patients with acute mania: A one‐year retrospective data from a tertiary care

Haddad¹,

Sacre²,

Hallit

et al. 2019

Perspect Psychiatr Care

View full text Add to dashboard Cite

Objective: To assess the prevalence of medical comorbidities in acute manic patients over a period of 1 year, and to evaluate correlates of the readmission rate. Design/Methods: A retrospective observational study was conducted on 158 acute manic patients from 2016 to 2017. Results: The most common physical comorbidity was obesity (36.1%) followed by cardiovascular disorders (15.2%) and liver dysfunctions (9.3%). Male gender was associated with higher readmission rate (Beta = −0.260), while taking anticholinergic drugs (Beta = −0.338) and having a family history of psychiatric disorders (Beta = −0.222) were associated with lower readmission rate. Practical implications: The study results may help physicians and other clinicians understand the burden of illness recurrence in bipolar disorder type I patients and adopt effective strategies to prevent relapse, taking into account all comorbidities.

show abstract

Section: Discussionsupporting

confidence: 89%

Prevalence of comorbidities and correlates of hospital readmission rate in patients with acute mania: A one‐year retrospective data from a tertiary care

Haddad¹,

Sacre²,

Hallit

et al. 2019

Perspect Psychiatr Care

View full text Add to dashboard Cite

show abstract

“…While the total prevalence of liver disease in patients with psychiatric illness is not fully known [29], the prevalence of MetS in schizophrenic or bipolar patients is remarkably high, ranging from 22 to 42% [30], compared to non-psychiatric control populations (with an estimated prevalence of 15-20%). A recent meta-analysis found patients suffering from severe mental illnesses to have a pooled RR of 1.58 (1.35-1.86) of developing MetS [2].…”

Section: Epidemiology and Natural Historymentioning

confidence: 99%

“…In psychiatric patients, the effects of medication also need to be taken into account, as psychiatric treatments may have specific side effects on the liver. They also contribute greatly to weight gain, and the MetS itself [29]. Moreover, there seems to be an inherent risk of developing MetS in relation to psychiatric illness that is also present in non-treated individuals [2].…”

Section: Pathophysiology Of Nafld/nashmentioning

confidence: 99%

Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches

Soto-Angona

Anmella

Valdés-Florido

et al. 2020

BMC Med

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in over 5% of the parenchyma in the absence of excessive alcohol consumption. It is more prevalent in patients with diverse mental disorders, being part of the comorbidity driving loss of life expectancy and quality of life, yet remains a neglected entity. NAFLD can progress to non-alcoholic steatohepatitis (NASH) and increases the risk for cirrhosis and hepatic carcinoma. Both NAFLD and mental disorders share pathophysiological pathways, and also present a complex, bidirectional relationship with the metabolic syndrome (MetS) and related cardiometabolic diseases. Main text This review compares the demographic data on NAFLD and NASH among the global population and the psychiatric population, finding differences that suggest a higher incidence of this disease among the latter. It also analyzes the link between NAFLD and psychiatric disorders, looking into common pathophysiological pathways, such as metabolic, genetic, and lifestyle factors. Finally, possible treatments, tailored approaches, and future research directions are suggested. Conclusion NAFLD is part of a complex system of mental and non-communicable somatic disorders with a common pathogenesis, based on shared lifestyle and environmental risks, mediated by dysregulation of inflammation, oxidative stress pathways, and mitochondrial function. The recognition of the prevalent comorbidity between NAFLD and mental disorders is required to inform clinical practice and develop novel interventions to prevent and treat these complex and interacting disorders.

show abstract

“…In previous studies, not only psychiatric disorders but also cardiac and hepatic diseases were frequently seen. 42 , 43 This suggests that anxiety and stress present in individuals by physiological deterioration are deeply involved as personal factors in drug use, and it cannot be denied that the road to societal reintegration may be closed. These results suggested the need to prevent organ disease.…”

Section: Discussionmentioning

confidence: 99%

“…Many studies have reported that psychotropic drug abuse involved not only mental illness but also various diseases such as gastrointestinal diseases. 42 , 43 Therefore, we speculated that the organ damage was due to the psychotropic drugs taken. However, we could not identify psychotropic drug-specific organ damages.…”

Section: Discussionmentioning

confidence: 99%

Analysis of psychotropic drug-related deaths in south Osaka

Tani

Ikeda

Michiue

et al. 2018

SAR

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to investigate the occurrence of deaths due to psychotropic drugs in south Osaka during a 10-year period and discuss societal factors from a medical viewpoint.MethodsPsychotropic drug-related deaths were retrospectively investigated based on the forensic postmortem data of 1,746 decedents in 2005–2014, and we excluded cases in which stimulant drugs were detected. Of these, 133 cases (7.6%) were found to be psychotropic drug-related deaths and were analyzed.ResultsPsychotropic drug-related deaths occurred in 78 males (59%; age range, 14–95 years) and 55 females (41%; 20–84 years). The direct cause of death was acute drug intoxication in many cases, and of these, acute combined drug intoxication due to the use of multiple drugs accounted for 76% of the deaths. Most of these victims were found to have gastrointestinal and cardiovascular diseases. Cases of psychotropic drug-related deaths had especially poor medical conditions. In addition, tests were positive for blood alcohol in 23% of the cases.ConclusionThe descriptive results revealed several factors that may be related to psychotropic drug-related deaths. To prevent drug abuse, several factors were deemed to be important, including improvements in the medical state of an individual, the avoidance of social isolation, and from a medical standpoint, the management of prescription drugs by medical personnel.

show abstract

Liver Illness and Psychiatric Patients

Cited by 20 publications

References 77 publications

Prevalence of comorbidities and correlates of hospital readmission rate in patients with acute mania: A one‐year retrospective data from a tertiary care

Prevalence of comorbidities and correlates of hospital readmission rate in patients with acute mania: A one‐year retrospective data from a tertiary care

Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches

Analysis of psychotropic drug-related deaths in south Osaka

Contact Info

Product

Resources

About